Blueprint Medicines Corporation (0HOJ.L)
USD 97.85
(1.4%)
USD 97.85
(1.4%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 774.12 Million USD | 219.29% |
| 2022 | 242.45 Million USD | 117.62% |
| 2021 | 111.4 Million USD | 24.33% |
| 2020 | 89.6 Million USD | -6.61% |
| 2019 | 95.94 Million USD | 556.42% |
| 2018 | 14.61 Million USD | -10.5% |
| 2017 | 16.33 Million USD | 384.6% |
| 2016 | 3.37 Million USD | -14.64% |
| 2015 | 3.94 Million USD | -56.34% |
| 2014 | 9.04 Million USD | 215.82% |
| 2013 | 2.86 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 386.56 Million USD | -36.31% |
| 2024 Q1 | 597.93 Million USD | -22.76% |
| 2024 Q2 | 740.34 Million USD | 23.82% |
| 2023 Q4 | 774.12 Million USD | 515.0% |
| 2023 Q1 | 118.2 Million USD | -51.24% |
| 2023 FY | 774.12 Million USD | 219.29% |
| 2023 Q2 | 116.19 Million USD | -1.7% |
| 2023 Q3 | 125.87 Million USD | 8.33% |
| 2022 FY | 242.45 Million USD | 117.62% |
| 2022 Q4 | 242.45 Million USD | -0.62% |
| 2022 Q3 | 243.96 Million USD | 126.74% |
| 2022 Q2 | 107.59 Million USD | -1.76% |
| 2022 Q1 | 109.52 Million USD | -1.69% |
| 2021 FY | 111.4 Million USD | 24.33% |
| 2021 Q3 | 83.86 Million USD | -2.18% |
| 2021 Q4 | 111.4 Million USD | 32.84% |
| 2021 Q1 | 87.67 Million USD | -2.16% |
| 2021 Q2 | 85.73 Million USD | -2.2% |
| 2020 Q2 | 93.14 Million USD | -1.79% |
| 2020 Q3 | 91.4 Million USD | -1.86% |
| 2020 FY | 89.6 Million USD | -6.61% |
| 2020 Q4 | 89.6 Million USD | -1.97% |
| 2020 Q1 | 94.83 Million USD | -1.16% |
| 2019 Q3 | 97.5 Million USD | -1.51% |
| 2019 Q1 | 99.6 Million USD | 581.4% |
| 2019 Q4 | 95.94 Million USD | -1.6% |
| 2019 Q2 | 99 Million USD | -0.6% |
| 2019 FY | 95.94 Million USD | 556.42% |
| 2018 Q1 | 17 Million USD | 4.15% |
| 2018 FY | 14.61 Million USD | -10.5% |
| 2018 Q2 | 16.16 Million USD | -4.96% |
| 2018 Q3 | 15.32 Million USD | -5.21% |
| 2018 Q4 | 14.61 Million USD | -4.61% |
| 2017 Q3 | 11.99 Million USD | 62.31% |
| 2017 Q2 | 7.39 Million USD | 14.18% |
| 2017 Q4 | 16.33 Million USD | 36.15% |
| 2017 FY | 16.33 Million USD | 384.6% |
| 2017 Q1 | 6.47 Million USD | 92.05% |
| 2016 Q3 | 8.4 Million USD | -10.27% |
| 2016 FY | 3.37 Million USD | -14.64% |
| 2016 Q4 | 3.37 Million USD | -59.89% |
| 2016 Q2 | 9.36 Million USD | -9.28% |
| 2016 Q1 | 10.32 Million USD | 161.45% |
| 2015 Q1 | 8.65 Million USD | -4.31% |
| 2015 FY | 3.94 Million USD | -56.34% |
| 2015 Q2 | 12.49 Million USD | 44.46% |
| 2015 Q3 | 11.96 Million USD | -4.28% |
| 2015 Q4 | 3.94 Million USD | -67.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | 9.04 Million USD | 0.0% |
| 2014 FY | 9.04 Million USD | 215.82% |
| 2013 FY | 2.86 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -2018.792% |
| Dynavax Technologies Corporation | 256.91 Million USD | -201.316% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1764.141% |
| Perrigo Company plc | 4.07 Billion USD | 80.996% |
| Illumina, Inc. | 2.26 Billion USD | 65.777% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 97.783% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -77312.2% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 91.897% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 94.56% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -345.53% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 71.36% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -2768.181% |
| Waters Corporation | 2.35 Billion USD | 67.136% |
| Biogen Inc. | 7.33 Billion USD | 89.451% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -1931.603% |
| Evolus, Inc. | 126.54 Million USD | -511.732% |
| Adicet Bio, Inc. | 17.7 Million USD | -4272.829% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -1693.319% |
| bluebird bio, Inc. | 330.32 Million USD | -134.351% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -43.105% |
| FibroGen, Inc. | 170.45 Million USD | -354.15% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 71.696% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -3606.73% |
| Homology Medicines, Inc. | 44.05 Million USD | -1657.212% |
| Geron Corporation | 85.89 Million USD | -801.2% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 67.718% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -73.937% |
| Myriad Genetics, Inc. | 145 Million USD | -433.877% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -61338.254% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -571.13% |
| Zoetis Inc. | 6.8 Billion USD | 88.621% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -17485.688% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 64.289% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 31.728% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 4.24% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -2031.217% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 46.742% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -1237.645% |
| Verastem, Inc. | 41.55 Million USD | -1762.796% |
| Nektar Therapeutics | 230.4 Million USD | -235.989% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -315.364% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -25082.889% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 44.579% |
| OPKO Health, Inc. | 326.56 Million USD | -137.051% |
| Exelixis, Inc. | 189.94 Million USD | -307.553% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -80.701% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -512563.576% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -459.3% |
| Imunon, Inc. | 1.13 Million USD | -67847.578% |
| Insmed Incorporated | 1.2 Billion USD | 35.704% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 48.366% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1258.395% |
| TG Therapeutics, Inc. | 110.79 Million USD | -598.698% |
| Incyte Corporation | 38.28 Million USD | -1921.893% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 11.781% |